Senior executive with 25 years of experience, focused on driving growth and performance in healthcare products and services. Currently serving as CFO of CAQH, a provider of healthcare data solutions delivering accurate and timely data on 2M providers and 250M members to reduce administrative burdens.Previously spent 10.5 years as SVP of Corp. Dev. for PharMerica (pharmacy div. of KKR port co BrightSpring) a diversified company in Spec. Pharmacy, Home Infusion, and LTC pharmacy. Completed 55+ transactions, including 7+ new business platforms, as well as JVs, divestitures, and strategic organic initiatives, growing annual revenue by 3.6x from $1.7Bn to $6.3Bn. - Acquired, integrated and completed expansion transactions for Onco360 and CareMed, now the leading independent specialty pharmacy in the US, including adding non-Oncology therapies and hub and manufacturer services capabilities- Transacted, integrated and architected expansion plan for Amerita, currently a top 5 specialty home infusion platform, completing 15+ bolt-on acquisitions, and spearheading organic expansion in to Ambulatory Infusion Centers- Acquired and integrated OnePoint Patient Care, accelerating growth of unique hospice pharmacy PBM and dispensing model by leveraging PharMerica network footprint- Acquired substantially all of the Company's revenue outside of the legacy long-term care business, including specialty pharmacy, specialty home infusion, hospice pharmacy, specialty lite pharmacy, hospital pharmacy management and 3PL wholesaler businesses- In core LTC business, completed over 30 transactions with over $1.1Bn in revenue and 200k+ beds, adding customer volume, regional density and new product and service capabilities, and created the Company's first LTC pharmacy joint venture structures - Successfully represented the company in numerous legal matters, both M&A related and otherwise - Played a critical role in sponsor exit planning and the company's January 2024 IPOPreviously spent 10+ years as an investment banker, advocating for clients primarily in medical device, specialty pharma and HCIT. Sell-side experience includes numerous public and private placements, M&A engagements, leveraged loans and convertible bonds, totaling 50+ closed transactions and ~$10 billion in aggregate value. Also served as in business development and marketing for Boston Heart Dx, a Bain Capital portfolio company in healthcare diagnostics, performing financial analysis, marketing and partnership development with physician groups, hospital administrators, and industry partners.